Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small cell lung cancer

INTERVENTION: Patients started to receive erlotinib (150 mg, p.o.) daily after experiencing recurrence or disease progression after second‐line treatment. Treatment was continued until disease progression or unacceptable toxicity occurred. Doses were adjusted to 100 mg per day according to the toxicity. CONDITION: advanced non‐small cell lung cancer PRIMARY OUTCOME: overall response rate SECONDARY OUTCOME: overall survival time, safety,progression‐free survival INCLUSION CRITERIA: Pathologically confirmed inoperable stage IIIB or stage IV NSCLC ECOG performance status of 0‐2 naive for EGFR tyrosine kinase inhibitors two prior systemic chemotherapy regimens, one of which was a platinum‐containing regimen Adequate function of the bone marrow, liver and kidney